Bad Pharma How Medicine Is Broken And How We Can Fix It By Goldacre Ben 2013 Paperback

Bad Pharma Bad Pharma *Bad Pharma Bad Pharma Drug Truths* **Deadly Medicines and Organised Crime** Good Pharma **The Truth About the Drug Companies** Pharma Sickening **Drugs & Pharmaceutical Technology Handbook 3D Printing of Pharmaceuticals The Textbook of Pharmaceutical Medicine Dioscorides on Pharmacy and Medicine** *Drugs for Life Big Pharma and Drug Pricing* Pharma and Profits **Marijuana As Medicine?** *Big Pharma* China Rx Butchered by "Healthcare": What to Do About Doctors, Big Pharma, and Corrupt Government Ruining Your Health and Medical Care *Deadly Medicines and Organised Crime* **Pharmaceuticals in the Environment** *Drug Wars* Pharma's Prescription *Hooked Big Pharma, Big Greed (Second Edition)* Pharmageddon Careers with the Pharmaceutical Industry Pharmaceutical Medicine and Translational Clinical Research *The Antidote* **Modern Pharmaceutical Industry** *Pharmaceutical Calculations White Market Drugs* The Illusion of Evidence-Based Medicine Pharmacy and Medicines Law in Ireland **Ghost-Managed Medicine Global Pharmaceuticals** *Access to Medicines as a Human Right* **A Brief History of Pharmacy**

Thank you definitely much for downloading **Bad Pharma How Medicine Is Broken And How We Can Fix It By Goldacre Ben 2013 Paperback**.Most likely you have knowledge that, people have see numerous times for their favorite books in imitation of this Bad Pharma How Medicine Is Broken And How We Can Fix It By Goldacre Ben 2013 Paperback, but end in the works in harmful downloads.

Rather than enjoying a good PDF subsequent to a cup of coffee in the afternoon, on the other hand they juggled next some harmful virus inside their computer. **Bad Pharma How Medicine Is Broken And How We Can Fix It By Goldacre Ben 2013 Paperback** is available in our digital library an online entrance to it is set as public for that reason you can download it instantly. Our digital library saves in compound countries, allowing you to acquire the most less latency times to download any of our books once this one. Merely said, the Bad Pharma How Medicine Is Broken And How We Can Fix It By Goldacre Ben 2013 Paperback is universally compatible like any devices to read.

Global Pharmaceuticals Aug 22 2019 DIVAnthropological study of the globalization of pharmaceuticals and its effects on local cultures, health, and economics./div

Sickening Jan 19 2022 The inside story of how Big Pharma’s relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health. The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals. In this no-holds-barred exposé, Dr. John Abramson—one of the foremost experts on the drug industry’s deceptive tactics—combines patient stories with what he learned during many years of serving as an expert in national drug litigation to reveal the tangled web of financial interests at the heart of the dysfunction in our health-care system. For example, one of pharma’s best-kept secrets is that the peer reviewers charged with ensuring the accuracy and completeness of the clinical trial reports published in medical journals do not even have access to complete data and must rely on manufacturer-influenced summaries. Likewise for the experts who write the clinical practice guidelines that define our standards of care. The result of years of research and privileged access to the inner workings of the U.S. medical-industrial complex, Sickening shines a light on the dark underbelly of American health care—and presents a path toward genuine reform.

Big Pharma, Big Greed (Second Edition) Aug 02 2020 UPDATED AND REVISED EDITION: Throughout his distinguished legal career, Stephen Sheller has relished the role of the underdog, evincing a sharply honed sense of fair play and justice. Early in his career, he represented Black Panthers in Philadelphia when they were arrested on trumped up murder and conspiracy charges. Later, he was in the vanguard of lawyers who took on the tobacco industry in the 1990s and he reprised that strategy a few years later in targeting Big Pharma for its harmful products and their deleterious effects on public health. In Big Pharma, Big Greed The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health Sheller tells a tale that is at once deeply personal but also with wide repercussions for the U.S. health care system and the hundreds of millions of Americans whose lives literally depend on it. Decades of litigating against the pharmaceutical industry taught Sheller one irreducible lesson: In too many instances, unneeded and at times dangerous drugs are foisted on the public without adequate warning as to risks, all in the service of boosting industry profits. All too often, achieving block buster status for a patent protected medication becomes an end in itself, as Big Pharma companies manipulate clinical trial data, draft scholarly articles for friendly physicians often in their pay, and market their drugs for uses that never had been approved by the federal Food and Drug Administration. This last practice proved to be something of an Achilles Heel for the industry. In litigation that resulted in settlement and fines in the billions, companies such as Eli Lilly acknowledged marketing drugs off label to a broad range of patients for whom the medications had never been approved. Sheller's litigation formed the basis for these settlements and the effort is ongoing. He and other plaintiffs' lawyers now are suing Janssen Pharmaceuticals for the adverse impacts of its drug, Risperdal, a second generation anti-psychotic that Sheller and others allege is linked to the growth of female breast tissue in young boys and men. Already there have been several big jury verdicts against Janssen with hundreds of more cases yet to be tried. In the book, Sheller not only recounts his major litigation battles but also makes sweeping proposals for industry reform. To restore regulatory credibility, Sheller proposes that responsibility for testing new medicines be taken away from the industry and given over to hospitals and other public entities partnering with government regulators. Pharmaceutical companies that betray the public trust would risk government- initiated dissolution. Harsh medicine to be sure, but Sheller believes entirely appropriate to the underlying malady.

Bad Pharma Aug 26 2022 We like to imagine that medicine is based on evidence and the results of fair testing and clinical trials. In reality, those tests and trials are often profoundly flawed. We like to imagine that doctors who write prescriptions for everything from antidepressants to cancer drugs to heart medication are familiar with the research literature about a drug, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality much of their education is funded by the pharmaceutical industry. We like to imagine that regulators have some code of ethics and let only effective drugs onto the market, when in reality they approve useless drugs, with data on side effects casually withheld from doctors and patients. All these problems have been shielded from public scrutiny because they're too complex to capture in a sound bite. But Ben Goldacre shows that the true scale of this murderous disaster fully reveals itself only when the details are untangled. He believes we should all be able to understand precisely how data manipulation works and how research misconduct in the medical industry affects us on a global scale. With Goldacre's characteristic flair and a forensic attention to detail, Bad Pharma reveals a shockingly broken system and calls for regulation. This is the pharmaceutical industry as it has never been seen before.

Ghost-Managed Medicine Sep 22 2019

Deadly Medicines and Organised Crime May 23 2022 PRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the pharmaceutical industries and their charade of fraudulent behaviour, both in research and marketing where the morally repugnant disregard for human lives is the norm. He convincingly draws close co

The Antidote Mar 29 2020 "This is the Moneyball of the pharma world, the story of one drug company's quest to transform the pharmaceutical industry and a deeply revealing look into a world where breakneck capitalism meets life-saving medicine.The $325 billion-a-year pharmaceutical business is America's most challenging and one of its most profitable. It is tougher in just about every way than any other enterprise: from the towering biological risks inherent in its mission to treat disease; to the thirty-to-one failure rate in bringing out a successful medicine after a candidate clears all the hurdles to get to human testing; to the billion-dollar-plus cost of ramping up a successful product; to operating in the worlds most highly regulated industry with the possible exception of nuclear power. The Antidote tells the story of Vertex, a maverick drug company led by the charismatic Joshua Boger and a small group of entrepreneurial young scientists who broke off from Merck when it was the world's best drug maker, indeed the most admired business in America because they thought they could make drugs better. Building upon his widely praised The Billion-Dollar Molecule, Barry Werth captures the full scope of Vertex's twenty-five-year drive to liver breakthrough medicines and transform the drug industry. The Antidote draws upon unprecedented inside reporting spanning more than two decades to provide a groundbreaking close-up of Vertex's inner workings and the ferocious but indispensable world it inhabits"--Provided by publisher.

Good Pharma Apr 22 2022 Drawing on key concepts in sociology and management, this history describes a remarkable institute that has elevated medical research and worked out solutions to the troubling practices of commercial pharmaceutical research. Good Pharma is the answer to Goldacre's Bad Pharma: ethical research without commercial distortions.

Hooked Sep 03 2020 This book explores the controversial relationship between physicians and the pharmaceutical industry, identifies the ethical tensions and controversies, and proposes numerous reforms both for medicine's own professional integrity and for effective public regulation of the industry.

Drug Wars Nov 05 2020 While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.

Dioscorides on Pharmacy and Medicine Sep 15 2021 For 1,600 years Dioscorides (ca. AD 40–80) was regarded as the foremost authority on drugs. He knew mild laxatives and strong purgatives, analgesics for headaches, antiseptics for wounds, emetics to rid one of ingested poisons, chemotherapy agents for cancer treatments, and even oral contraceptives. Why, then, have his works remained obscure in recent centuries? Because of one small oversight (Dioscorides himself thought it was self-evident): he failed to describe his method for organizing drugs by their affinities. This omission led medical authorities to use his materials as a guide to pharmacy while overlooking Dioscorides' most valuable contribution—his empirically derived method for observing and classifying drugs by clinical testing. Dioscorides' De materia medica, a five-volume work, was written in the first century. Here revealed for the first time is the thesis that Dioscorides wrote more than a lengthy guide book. He wrote a great work of science. He had said that he discovered the natural order and would demonstrate it by his arrangement of drugs from plants, minerals, and animals. Until John M. Riddle's pathfinding study, no one saw the genius of his system. Botanists from the eighteenth century often attempted to find his unexplained method by identifying the sequences of his plants according to the Linnean system but, while there are certain patterns, there remained inexplicable incoherencies. However, Dioscorides' natural order as set down in De materia medica was determined by drug affinities as detected by his acute, clinical ability to observe drug reactions in and on the body. So remarkable was his ability to see relationships that, in some cases, he saw what we know to be common chemicals shared by plants of the same and related species and other natural product drugs from animal and mineral sources. Western European and Islamic medicine considered Dioscorides the foremost authority on drugs, just as Hippocrates is regarded as the Father of Medicine. They saw him point the way but only described the end of his finger, despite the fact that in the sixteenth century alone there were over one hundred books published on him. If he had explained what he thought to be self-evident, then science, especially chemistry and medicine, would almost certainly have developed differently. In this culmination of over twenty years of research, Riddle employs modern science and anthropological studies innovatively and cautiously to demonstrate the substance to Dioscorides' authority in medicine.

Big Pharma Apr 10 2021 Pharmaceutical medicine is very, very big business. The top ten players earned more than $200 billion in 2003. One drug, Pfizer's cholesterol pill Lipitor, had sales of more than $9 billion. This kind of money buys an awful lot of friends among doctors and politicians. Most of those involved in the formulation of public health policy seems happy with the present system. The trouble is that the public is starting to have doubts. There is a growing sense that the vast profits of drug companies and their control of the research agenda might not be that good for our health. Jacky Law takes the reader on a journey through the pharmaceutical business and shows how the public is quite right to be concerned about conventional medicine, as it has developed since the late 1970s. She tells a story of spectacular regulatory failure, phenomenally high prices, betrayal of the public interest and a growing awareness among ordinary people that things could be very different. Sophisticated marketing and public relations, not scientific excellence, have helped corporations to preside unchallenged over matters of life and death. It is time, Law argues, for us to take responsibility for our health, not as passive consumers of pharmaceutical medicine, but as informed citizens.

Butchered by "Healthcare": What to Do About Doctors, Big Pharma, and Corrupt Government Ruining Your Health and Medical Care Feb 08 2021 HOW YOU CAN SURVIVE "HEALTHCARE," THE LARGEST AND MOST CORRUPT INDUSTRY IN AMERICA. □ Learn what works. □ See through the lies. □ Handle hospitals. □ Find trustworthy doctors. □ Master your drugs and quit them with confidence. □ Consider holistic medicine. Healthcare is the top cause of all our overdue debts and personal bankruptcy. Our medical spending per person is double that of other countries', but fully half the treatments are ineffective or harmful. Immense, predatory industries such as angioplasty and coronary artery bypass surgery victimize us. These procedures cause complications and deaths, but few patients survive even a day longer. Most back and endoscopic knee surgeries are equally worthless. Seventy percent of us are on prescriptions, and 20 percent take over five. One in six uses psychiatric medicine, which commonly causes irreversible brain damage and premature death. Millions are now addicted to prescription opioids. Fifty-thousand people die each year from overdoses. The FDA allows big Pharma to falsify the studies required to patent drugs. These corporations hire armies of ghostwriters to stuff websites and medical journal articles with marketing lies. Finding the truth is now nearly impossible. But all this gets overlooked as the companies pay billions of dollars in criminal settlements nearly every year. Money short-circuits everyone's integrity, but there is an alternative. Patients and doctors can still prevail. Learn the system, and you can too.

Drugs & Pharmaceutical Technology Handbook Dec 18 2021 Drugs and pharmaceutical industry plays a vital role in the economic development of a nation. It is one of the largest and most advanced sectors in the world, acting as a source for various drugs, medicines and their intermediates as well as other pharmaceutical formulations. India has come a long way in this field, from a country importing more than 95% of its requirement of drugs and pharmaceuticals; India now is exporting it even to developed countries. Being the intense knowledge driven industry, it offers innumerable business opportunities for the investors/ corporate the world over. The existence of well defined and strong pharmaceutical industry is important for promoting and sustaining research and developmental efforts and initiatives in an economy as well as making available the quality medicines to all at affordable prices. That is, it is essential to improve the health status of the individuals as well as the society as a whole, so that positive contributions could be made to the economic growth and regional development of a country. On the global platform, India holds fourth position in terms of volume and thirteenth position in terms of value of production in pharmaceuticals. The pharmaceutical industry has been producing bulk drugs belonging to all major therapeutic groups requiring complicated manufacturing processes as well as a wide range of pharmaceutical machinery and equipments. The modern Indian Pharmaceutical Industry is recent and its foundation was laid in the beginning of the current century. The pharmaceutical industry can be broadly categorised as bulk drugs, formulations, IV fluids and pharmaceutical aids (such as medical equipment, hospital disposables,

capsules, etc.). Special feature of the pharmaceutical industry is a large number of manufacturers in the small scale sector. The government is also encouraging the SSI sector providing some incentives. The recent developments in the technology and R & D work in this field have led to the increased growth rate of industries and have established Indian Pharmaceutical industries in the international market. The content of the book includes information about properties, general methods of analysis, methods of manufacture, of different types of drugs and pharmaceuticals. Some of the fundamentals of the book are polymeric materials used in drug delivery systems , theoretical aspects of friction and lubrication , a convenient method for conversion of quinine to quinidine, formulation and evaluation of bio-available enteric-coated erythromycin and metronidazole tablets, extraction of virginiamycin, antipyretics and analgesics, column chromatographic assay of aspirin tablets, differentiating titration of phenacetin and caffeine, infrared spectra of some compounds of pharmaceutical interest etc. This book covers an intensive study on manufacturing, production, formulation and quality control of drugs and pharmaceuticals with technology involved in it. This book is an invaluable resource for technologists, professionals and those who want to venture in this field.

Drugs for Life Aug 14 2021 Challenges our understanding of health, risks, facts, and clinical trials [Payot]

Pharma and Profits Jun 12 2021 High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis C mRNA vaccines and the race for a cure Why the government does not deserve a piece of Biopharma’s profits Paying for drugs whose ultimate value is unknown The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

Bad Pharma Oct 28 2022 Argues that doctors are deliberately misinformed by profit-seeking pharmaceutical companies that casually withhold information about drug efficacy and side effects, explaining the process of pharmaceutical data manipulation and its global consequences. By the best-selling author of Bad Science.

Bad Pharma Jul 25 2022 Following the bestselling 'Bad Science', which mercilessly exposed the evils of bogus, pseudo-scientific remedies, Ben Goldacre puts the global pharmaceutical industry under the microscope.

Careers with the Pharmaceutical Industry May 31 2020 In recent years, many factors have combined to change the operating environment of the international pharmaceutical industry leading to greater specialisation and sophistication. This new edition will give an update of the different opportunities in drug discovery and development and the scientific, medical or other specialist training needed to accomplish them. The scope of this edition has been broadened to encompass all major roles, including marketing and sales.

Pharmaceuticals in the Environment Dec 06 2020 Medicines play an important role in the treatment and prevention of disease in humans and animals, but residues from these medicines can be released into the environment through a number of routes during their manufacture, use and disposal. It is only recently that the potential environmental impacts of this exposure to pharmaceuticals are being considered. The book explores where pharmaceutical residues can be found, e.g. in surface waters, drinking water, sediments and the marine environment; the sources of these residues, from manufacture through to disposal of unused medicines; how these residues break down; and how this all impacts on wildlife and human health. In reviewing the current position and examining further possible impacts, this book is an important reference for researchers working in the pharmaceutical industry, as well as for environmentalists, policy makers and students on pharmacy and environmental science courses wanting to better understand the impacts of pharmaceuticals on the environment.

White Market Drugs Dec 26 2019 The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs, David Herzberg explores these crises and the drugs that fueled them, from Bayer’s Heroin to Purdue’s OxyContin and all the drugs in between: barbiturate “goof balls,” amphetamine “thrill pills,” the “love drug” Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls “white markets,” where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its “drug wars”—until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America’s divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself—ideas that have been failing us catastrophically for over a century.

Marijuana As Medicine? May 11 2021 Some people suffer from chronic, debilitating disorders for which no conventional treatment brings relief. Can marijuana ease their symptoms? Would it be breaking the law to turn to marijuana as a medication? There are few sources of objective, scientifically sound advice for people in this situation. Most books about marijuana and medicine attempt to promote the views of advocates or opponents. To fill the gap between these extremes, authors Alison Mack and Janet Joy have extracted critical findings from a recent Institute of Medicine study on this important issue, interpreting them for a general audience. Marijuana As Medicine? provides patientsâ€"as well as the people who care for themâ€"with a foundation for making decisions about their own health care. This empowering volume examines several key points, including: Whether marijuana can relieve a variety of symptoms, including pain, muscle spasticity, nausea, and appetite loss. The dangers of smoking marijuana, as well as the effects of its active chemical components on the immune system and on psychological health. The potential use of marijuana-based medications on symptoms of AIDS, cancer, multiple sclerosis, and several other specific disorders, in comparison with existing treatments. Marijuana As Medicine? introduces readers to the active compounds in marijuana. These include the principal ingredient in Marinol, a legal medication. The authors also discuss the prospects for developing other drugs derived from marijuana's active ingredients. In addition to providing an up-to-date review of the science behind the medical marijuana debate, Mack and Joy also answer common questions about the legal status of marijuana, explaining the conflict between state and federal law regarding its medical use. Intended primarily as an aid to patients and caregivers, this book objectively presents critical information so that it can be used to make responsible health care decisions. Marijuana As Medicine? will also be a valuable resource for policymakers, health care providers, patient counselors, medical faculty and studentsâ€"in short, anyone who wants to learn more about this important issue.

Pharmacy and Medicines Law in Ireland Oct 24 2019 -sources of Irish law. --

Pharmaceutical Calculations Jan 27 2020

The Textbook of Pharmaceutical Medicine Oct 16 2021 New edition of succesful standard reference book for thepharmaceutical industry and pharmaceutical physicians! The Textbook of Pharmaceutical Medicine is the coursebookfor the Diploma in Pharmaceutical Medicine, and is used as astandard reference throughout the pharmaceutical industry. The newedition includes greater coverage of good clinical practice, acompletely revised statistics chapter, and more on safety. Coversthe course information for the Diploma in PharmaceuticalMedicine Fully updated, with new authors Greater coverage of good clinical practice and safety New chapters on regulation of medical devices in Europe andregulation of therapeutic products

in Australia
3D Printing of Pharmaceuticals Nov 17 2021 3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Abdul W. Basit is Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multidisciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late-stage clinical trials. He has published over 350 papers, book chapters and abstracts and delivered more than 250 invited research presentations. Abdul is also a serial entrepreneur and has filed 25 patents and founded 3 pharmaceutical companies (Kuecept, Intract Pharma, FabRx). Abdul is a frequent speaker at international conferences, serves as a consultant to many pharmaceutical companies and is on the advisory boards of scientific journals, healthcare organisations and charitable bodies. He is the European Editor of the International Journal of Pharmaceutics. Abdul was the recipient of the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS) and is the only non-North American scientist to receive this award. He was also the recipient of the Academy of Pharmaceutical Sciences (APS) award. Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters and 4 authored books. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, and he is an expert in the physico-chemical characterisation of compounds and formulations with thermal methods and calorimetry.
Access to Medicines as a Human Right Jul 21 2019 According to the World Health Organization, one-third of the global population lacks access to essential medicines. Should pharmaceutical companies be ethically or legally responsible for providing affordable medicines for these people, even though they live outside of profitable markets? Can the private sector be held accountable for protecting human beings' right to health? This thought-provoking interdisciplinary collection grapples with corporate responsibility for the provision of medicines in low- and middle-income countries. The book begins with an examination of human rights, norms, and ethics in relation to the private sector, moving to consider the tensions between pharmaceutical companies' social and business duties. Broad examinations of global conditions are complemented by case studies illustrating different approaches for addressing corporate conduct. Access to Medicines as a Human Right identifies innovative solutions applicable in both global and domestic forums, making it a valuable resource for the vast field of scholars, legal practitioners, and policymakers who must confront this challenging issue.
Pharma's Prescription Oct 04 2020 The pharmaceutical industry needs a shot in the arm – and not a moment too soon. The executive suite is mired in a bygone era, a time when extensive, well-funded pharmaceutical R&D produced blockbuster drugs, kept everything in-house and reaped the financial rewards. But that way of working needs to change. Executives now need to know what the technologists in their companies are doing in order to survive the next decade. Written for those new to industry, as well as for experienced professionals or specialists looking to expand their knowledge, this book is a must-read for business executives and information technologists alike. Pharma's Prescription bridges the knowledge gap between current business practices and the most valuable technologies today. This book is filled with practical, real-life examples from industry and is a straightforward guide for all pharmaceutical and information technology executives who need to improve their businesses. Focuses on practical solutions that are easily incorporated in your day-to-day work Integrates business operations and information technology Highlights the industry's top turn-around stories Discusses pharmaceutical industry trends, growth opportunities, innovation drivers, regulatory complexities, and emerging market operations
Drug Truths Jun 24 2022 This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.
The Truth About the Drug Companies Mar 21 2022 During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue change. Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers. Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective. The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.
Bad Pharma Sep 27 2022 We all feel uncomfortable about the role of profit in healthcare, we all have a vague notion that the global $600bn pharmaceutical industry is somehow evil and untrustworthy, but that sense rarely goes beyond a flaky, undifferentiated new age worldview. Bad Pharma puts real flesh on those bones, revealing the rigged evidence used by drug companies. Bad information means bad treatment decisions, which means patients suffer and die: there is no climactic moment of villainy, but drugs are used which are overpriced, less effective, and have more side effects. There are five cheap, easy things we can do to fix the problem. Bad Pharma takes a big dirty secret out into the open, and will provide a single focus for concerns people have both inside and outside medicine.
Modern Pharmaceutical Industry Feb 26 2020 Modern Pharmaceutical Industry: A Primer comprehensively explains the broad range of divisions in the complex pharmaceutical industry. Experts actively involved in each component discuss their own contribution to a pharmaceutical company's work and success. Divisions include regulatory affairs, research and development, intellectual property, pricing, marketing, generics, OTC, and more.

The seventeen chapters included in this resource offer a wide range of topics, from discovery and formulation to post-approval and legal. Readers will be given a detailed look at the structure of a contemporary drug company and a thorough understanding of what goes on behind the scenes. Modern Pharmaceutical Industry: A Primer is a valuable resource for all pharmacy students, new hires at pharmaceutical companies, drug company management, and academic health center libraries. No other text provides a comprehensive look at one of the most dynamic industries related to the modern healthcare system.

Deadly Medicines and Organised Crime Jan 07 2021

Pharma Feb 20 2022 "Exorbitant prices for lifesaving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on prescription opioids have caused many to lose faith in pharmaceutical companies. Now, Americans are demanding national reckoning with a monolithic industry. In Pharma, award-winning journalist and New York Times best-selling author Gerald Posner uncovers the real story of the Sacklers, the family that became one of America's wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the centure of the opioid crisis. The unexpected twists and turns of the Sakler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. Pharma reveals how and why American drug companies have put earnings ahead of patients"--

The Illusion of Evidence-Based Medicine Nov 24 2019 An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine.

China Rx Mar 09 2021 Millions of Americans are taking prescription drugs made in China and don't know it-- and pharmaceutical companies are not eager to tell them. This probing book examines the implications for the quality and availability of vital medicines for consumers. Several decades ago, penicillin, vitamin C, and many other prescription and over-the-counter products were manufactured in the United States. But with the rise of globalization, antibiotics, antidepressants, birth control pills, blood pressure medicines, cancer drugs, among many others are made in China and sold in the United States. China's biggest impact on the US drug supply is making essential ingredients for thousands of medicines found in American homes and used in hospital intensive care units and operating rooms. The authors convincingly argue that there are at least two major problems with this scenario. First, it is inherently risky for the United States to become dependent on any one country as a source for vital medicines, especially given the uncertainties of geopolitics. For example, if an altercation in the South China Sea causes military personnel to be wounded, doctors may rely upon medicines with essential ingredients made by the adversary. Second, lapses in safety standards and quality control in Chinese manufacturing are a risk. Citing the concerns of FDA officials and insiders within the pharmaceutical industry, the authors document incidents of illness and death caused by contaminated medications that prompted reform. This is a disturbing, well-researched book and a wake-up call for improving the current system of drug supply and manufacturing.

Pharmaceutical Medicine and Translational Clinical Research Apr 29 2020 Pharmaceutical Medicine and Translational Clinical Research covers clinical testing of medicines and the translation of pharmaceutical drug research into new medicines, also focusing on the need to understand the safety profile of medicine and the benefit-risk balance. Pharmacoeconomics and the social impact of healthcare on patients and public health are also featured. It is written in a clear and straightforward manner to enable rapid review and assimilation of complex information and contains reader-friendly features. As a greater understanding of these aspects is critical for students in the areas of pharmaceutical medicine, clinical research, pharmacology and pharmacy, as well as professionals working in the pharmaceutical industry, this book is an ideal resource. Includes detailed coverage of current trends and key topics in pharmaceutical medicine, including biosimilars, biobetters, super generics, and Provides a comprehensive look at current and important aspects of the science and regulation of drug and biologics discovery

A Brief History of Pharmacy Jun 19 2019 Pharmacy has become an integral part of our lives. Nearly half of all 300 million Americans take at least one prescription drug daily, accounting for $250 billion per year in sales in the US alone. And this number doesn't even include the over-the-counter medications or health aids that are taken. How did this practice become such an essential part of our lives and our health? A Brief History of Pharmacy: Humanity's Search for Wellness aims to answer that question. As this short overview of the practice shows, the search for well-being through the ingestion or application of natural products and artificially derived compounds is as old as humanity itself. From the Mesopotamians to the corner drug store, Bob Zebroski describes how treatments were sought, highlights some of the main victories of each time period, and shows how we came to be people who rely on drugs to feel better, to live longer, and look younger. This accessible survey of pharmaceutical history is essential reading for all students of pharmacy.

Big Pharma and Drug Pricing Jul 13 2021 Americans pay among the highest prices for prescription drugs, thanks to government legislation and the powerful pharmaceutical lobbies. The effect has been disastrous, with many citizens obtaining cheaper medicine from Canada, and others forgoing it altogether at the risk of their health. These crippling prices are set by big pharma, at the insistence of those who support free trade. Consumers call the pharmaceutical companies greedy and selfish, but these companies also enact change, through scientific research, curing of diseases, and community outreach. What is the answer to this complex issue? Readers will learn about the conflicts and potential solutions in this compelling volume.

Pharmageddon Jul 01 2020 This searing indictment, David Healy’s most comprehensive and forceful argument against the pharmaceuticalization of medicine, tackles problems in health care that are leading to a growing number of deaths and disabilities. Healy, who was the first to draw attention to the now well-publicized suicide-inducing side effects of many anti-depressants, attributes our current state of affairs to three key factors: product rather than process patents on drugs, the classification of certain drugs as prescription-only, and industry-controlled drug trials. These developments have tied the survival of pharmaceutical companies to the development of blockbuster drugs, so that they must overhype benefits and deny real hazards. Healy further explains why these trends have basically ended the possibility of universal health care in the United States and elsewhere around the world. He concludes with suggestions for reform of our currently corrupted evidence-based medical system.